Stock comparison
IDEXX Laboratories
West Pharmaceutical Services
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
WST
West Pharmaceutical Services
Market cap
$21.21B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | WST | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 55C | IDXX |
| Benjamin Graham | 72B | 80A | WST |
| Philip Fisher | 67B | 39D | IDXX |
| Peter Lynch | 63C | 16F | IDXX |
| Joel Greenblatt | 75B | 52C | IDXX |
| Charlie Munger | 79B | 52C | IDXX |
| Terry Smith | 76B | 46D | IDXX |
Side-by-side metrics
| Metric | IDXX | WST |
|---|---|---|
| Market cap | $42.11B | $21.21B |
| P/E (TTM) | 39.0x | 39.8x |
| EV/EBIT | 31.6x | 34.0x |
| ROIC (TTM) | 40.66% | 15.24% |
| Gross margin | 62.05% | 36.24% |
| Net margin | 24.63% | 16.85% |
| Revenue CAGR 5y | 7.56% | 2.08% |
| EPS CAGR 5y | 10.79% | -6.4% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.29% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -6.4%+159%
- Revenue CAGR 5y7.56%vs 2.08%+72%
- ROIC (TTM)40.66%vs 15.24%+63%
- Market cap$42.11Bvs $21.21B+50%
WST leads on
- Dividend yield0.29%vs 0.0%+100%
- Debt / Equity0.1xvs 0.7x+85%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.